in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Fresenius Kabi Increases Stake in Dabur Pharma
10:18 AM MDT | August 25, 2008 | Deepti Ramesh
Fresenius Kabi (Bad Homburg, Germany), a unit of health care group Fresenius SE, says it has completed the acquisition of Indian generics and active pharmaceutical ingredients (API) firm Dabur Pharma (New Delhi), with the purchase of a further 17.6% stake in the firm. Fresenius Kabi acquired 73.3% stake in Dabur Pharma in April for about €139 million ($224 million) (CW, April 28, p. 29). Relevant approvals required under the Indian law have also been secured, Fresenius Kabi says. Dabur Pharma is a manufacturer and supplier of generic drugs and APIs to...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee